CTLA-4, LAG-3, TIGIT & Other Checkpoints

Cat. No.

AT0431

CAS No.

2490556-50-6

Vobramitamab

Synonyms: AEX-4089

Vobramitamab is a humanized monoclonal antibody targeting B7-H3, conjugated to the prodrug seco-DUBA through a cleavable linker to create the antibody-drug conjugate (ADC) MGC018. This ADC has demonstrated potent antitumor efficacy in preclinical models across a variety of cancers, including breast, ovarian, lung cancer, and melanoma. MGC018's design allows for targeted delivery of the cytotoxic agent to tumor cells, minimizing systemic exposure and enhancing therapeutic potential.

Cat. No.

AT0460

CAS No.

2723442-10-0

Rolistobart

Rolistobart is a humanized monoclonal antibody of the immunoglobulin G4-kappa subtype, specifically targeting LILRB4/CD85k. It functions as both an immunostimulant and an antineoplastic agent, designed to modulate immune responses and inhibit tumor growth. This antibody is utilized primarily in the study of cancer immunotherapy, focusing on its potential to enhance immune system recognition and destruction of cancer cells.

Cat. No.

AT0472

CAS No.

2148321-69-9

Zalifrelimab

Synonyms: AGEN1884

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody designed to specifically target and inhibit CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). By antagonizing the inhibitory checkpoints mediated by CTLA-4 signaling, Zalifrelimab enhances immune cell activation, potentially amplifying antitumor immune responses. This antibody is utilized in research focused on immunotherapy and the modulation of immune checkpoints in oncology.

Cat. No.

AT0508

CAS No.

1803176-05-7

Oleclumab

Synonyms: MEDI9447

Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody designed to selectively target and inhibit the exonuclease activity of CD73, an extracellular enzyme. By modulating the activity of CD73, Oleclumab influences the composition of bone marrow and lymphoid infiltrating leukocyte populations within the tumor microenvironment, demonstrating significant anti-tumor activity. This antibody is pivotal in studies focused on tumor immunology and the development of cancer immunotherapies.

Cat. No.

AT0521

CAS No.

2168561-20-2

Nurulimab

Synonyms: BCD-145

Nurulimab (BCD-145) is a human monoclonal antibody that targets cytotoxic T lymphocyte antigen-4 (CTLA-4). This antibody is specifically designed for use in melanoma research, where it can help investigate the role of CTLA-4 in tumor immunity and potential therapeutic interventions.

Cat. No.

AT0582

CAS No.

745013-59-6

Tremelimumab

Synonyms: Ticilimumab; CP-675206

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Cat. No.

AT0592

CAS No.

2581724-89-0

Ralzapastotug

Synonyms: AB-308

Ralzapastotug (AB-308) is a monoclonal antibody of the IgG1 subclass designed to specifically target the TIGIT receptor (T cell immunoreceptor with Ig and ITIM domains). This antibody binds to the amino acid sequence 106-126 of the cellular prion protein PrP^C, indicating a precise specificity that may be critical in modulating immune responses. Ralzapastotug is particularly relevant in research focused on immune checkpoint pathways and could be instrumental in studies exploring therapeutic interventions in oncology and immunological disorders.

Cat. No.

AT0616

CAS No.

2786639-04-9

Brivestobart

Brivestobart is a human monoclonal antibody of the IgG4κ subtype designed to target LAG3. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity makes Brivestobart suitable for research focused on the modulation of immune checkpoint pathways, particularly in the context of immunotherapy and cancer research.

Cat. No.

AT0627

CAS No.

2173096-82-5

Encelimab

Encelimab is a monoclonal antibody targeting LAG-3 (Lymphocyte-activation gene 3). By inhibiting the interaction between LAG-3 and MHC class II molecules, Encelimab promotes T-cell activation and enhances immune responses. Studies have demonstrated that Encelimab, both as a monotherapy and in conjunction with an anti-PD-1 antibody, effectively reduces tumor volume in a lymphoma mouse model using A20 cell xenografts. This antibody is pivotal for research focused on immunotherapy and cancer immunology, particularly in understanding and manipulating T-cell responses in oncological models.

Cat. No.

AT0630

CAS No.

1073059-33-2

Samalizumab

Synonyms: ALXN 6000

Samalizumab (ALXN 6000) is a humanized monoclonal antibody engineered to selectively target and bind to CD200, effectively inhibiting its interaction with the CD200 receptor (CD200R). This antibody is utilized in the study of multiple myeloma and B-cell chronic lymphocytic leukemia, offering a valuable tool for researchers exploring the pathophysiological roles and therapeutic potential of CD200-CD200R signaling in these hematological malignancies.

Cat. No.

AT0662

Anti-CTLA-4/CD152 Antibody

The Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CTLA-4 (CD152). This antibody comprises a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa. This antibody is essential for research focusing on immune checkpoint regulation and cancer immunotherapy.

Cat. No.

AT0684

CAS No.

2750031-14-0

Firastotug

Synonyms: ADG-116

Firastotug is an IgG1κ monoclonal antibody specifically designed to target CTLA-4, a critical immune checkpoint protein associated with cytotoxic T lymphocytes. CTLA-4 plays a pivotal role in regulating immune responses, making it a significant target in the study of autoimmunity and oncology. This antibody is instrumental for researchers focusing on the modulation of immune checkpoints to understand disease mechanisms and develop therapeutic strategies.

Cat. No.

AT0689

CAS No.

2829250-32-8

Ansipastobart

Ansipastobart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets NT5E. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.

Cat. No.

AT0699

CAS No.

2022215-65-0

Cobolimab

Synonyms: TSR-022; GSK4069889

Cobolimab (TSR-022) is a monoclonal antibody targeting the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This antibody facilitates the internalization of TIM-3, exhibiting potent activity with an IC50 value of 0.4464 nM. Cobolimab is primarily investigated for its therapeutic potential in the treatment of solid tumors and non-small cell lung cancer (NSCLC), highlighting its relevance in oncological research and therapeutic applications.

Cat. No.

AT0702

CAS No.

2927399-38-8

Solnerstotug

Solnerstotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets V-set immunoregulatory receptor (VSIR). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is designed for use in research studies focused on immune regulation and VSIR-mediated pathways.

Cat. No.

AT0713

CAS No.

1895083-75-6

Omburtamab

Omburtamab is a monoclonal antibody targeting CD276, also known as B7-H3, which is a member of the B7/CD28 immunoglobulin superfamily. CD276 is prominently expressed in a variety of solid human tumors. This antibody has the capability to specifically bind to tumor tissues, making it a valuable tool for research in cancer biology and therapeutic development across multiple cancer types.

Cat. No.

AT0715

CAS No.

2359413-58-2

Bapotulimab

Synonyms: BAY-1905254

Bapotulimab (BAY-1905254) is a fully humanized IgG2 monoclonal antibody designed to specifically target the immunoglobulin-like domain containing receptor 2 (ILDR2). This antibody exhibits potent antitumor activity and immunosuppressive properties, making it a valuable tool for research in cancer immunotherapy and immune regulation.

Cat. No.

AT0720

CAS No.

2451856-97-4

Mupadolimab

Synonyms: CPI-006

Mupadolimab (CPI-006) is a humanized IgG1κ monoclonal antibody designed to selectively target CD73 with modified FcγR binding properties to reduce effector function. This antibody is engineered to activate CD73-positive B cells, playing a crucial role in modulating immune responses. Its unique mechanism and specificity make it an invaluable tool for research focused on immunology and oncology, particularly in studies exploring the regulation of the immune checkpoint pathways.

Cat. No.

AT0745

CAS No.

2649362-29-6

Dargistotug

Synonyms: M-6223

Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody designed to specifically target TIGIT (T cell immune receptor with Ig domain and ITIM domains). TIGIT serves as an inhibitory immune checkpoint that plays a critical role in immune regulation by promoting NK cell depletion and diminishing cytokine secretion through its interaction with CD155. This antibody has the capability to inhibit effector T cell functions and enhance the regulation of T regulatory cells, contributing to its immunosuppressive effects. Dargistotug is pivotal in studies focused on immune checkpoint blockade and the modulation of immune responses in various diseases.

Cat. No.

AT0754

CAS No.

2484870-90-6

Ifinatamab

Ifinatamab is a monoclonal antibody of the immunoglobulin G1-kappa subclass, designed to target and inhibit the human B7 homolog 3 protein (B7-H3). This antibody functions as an immunomodulator, leveraging glycoengineering to enhance its efficacy and stability. Ifinatamab is specifically developed for its potential therapeutic applications in modulating immune responses against various pathological conditions where B7-H3 is implicated.

Cat. No.

AT0765

CAS No.

2342597-90-2

Surzebiclimab

Synonyms: BGB-A425

Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody that specifically targets the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This antibody exhibits a high affinity for the extracellular domain of human TIM-3, with a dissociation constant (K_D) of 0.36 nM, indicating strong and specific binding. Surzebiclimab is primarily utilized in the research of cancer immunotherapy, exploring pathways for enhancing immune responses against tumors.

Cat. No.

AT0780

CAS No.

1969313-51-6

Onvatilimab

Synonyms: JNJ-61610588

Onvatilimab (JNJ-61610588) is a human IgG1κ monoclonal antibody that targets VISTA (V-domain Ig Suppressor of T-cell Activation), a protein involved in the negative regulation of T-cell responses. This antibody exhibits potent anti-tumor activity by modulating the immune system's ability to recognize and destroy cancer cells. Onvatilimab is primarily researched for its therapeutic potential in oncology, particularly in enhancing immune-mediated tumor suppression.

Cat. No.

AT0820

CAS No.

2928515-12-0

Mavrostobart

Mavrostobart is a human monoclonal antibody of the IgG4κ isotype that specifically targets NT5E (CD73). For experimental control purposes, the recommended isotype control is Human IgG4 (S228P) kappa. This antibody is designed for precise binding to NT5E, making it highly relevant for research into its role in immunoregulation and tumor progression.

Cat. No.

AT0853

CAS No.

2924808-29-5

Felmetatug

Felmetatug is a human monoclonal antibody of the IgG1κ subtype that specifically targets VTCN1. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0866

CAS No.

2231068-83-8

Favezelimab

Synonyms: MK-4280

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3, designed to inhibit the binding of LAG-3 to MHC class II molecules. This interaction blockade enhances T-cell function and may potentiate an anti-tumor immune response. Favezelimab is primarily investigated for its therapeutic potential in colorectal cancer research, particularly in combination with the PD-L1 inhibitor Pembrolizumab, to synergistically enhance immune-mediated tumor suppression.